A Novel Three-Gene Model Predicts Prognosis and Therapeutic Sensitivity in Esophageal Squamous Cell Carcinoma. (25th November 2019)

• Record Type: Journal Article
• Authors: Zeng, Fa-Min; He, Jian-Zhong; Wang, Shao-Hong; Liu, De-kai; Xu, Xiu-E.; Wu, Jian-Yi; Li, En-Min; Xu, Li-Yan
• Other Names: El-Naggar Amal Guest Editor.
• Is Part Of: BioMed research international. Volume 2019(2019)
• Publication Date: 2019-11-25
• Subjects: Medicine -- Periodicals; Biology -- Periodicals; Biotechnology -- Periodicals; Life sciences -- Periodicals; 610.5
• DOI: 10.1155/2019/9828637
• Languages: English
• ISSNs: 2314-6133

Abstract

Abstract : To precisely predict the clinical outcome and determine the optimal treatment options for patients with esophageal squamous cell carcinoma (ESCC) remains challenging. Prognostic models based on multiple molecular markers of tumors have been shown to have superiority over the use of single biomarkers. Our previous studies have identified the crucial role of ezrin in ESCC progression, which prompted us to hypothesize that ezrin-associated proteins contribute to the pathobiology of ESCC. Herein, we explored the clinical value of a molecular model constructed based on ezrin-associated proteins in ESCC patients. We revealed that the ezrin-associated proteins (MYC, PDIA3, and ITGA5B1) correlated with the overall survival (OS) and disease-free survival (DFS) of patients with ESCC. High expression of MYC was associated with advanced pTNM-stage (P = 0.011 ), and PDIA3 and ITGA5B1 were correlated with both lymph node metastasis (PDIA3: P < 0.001 ; ITGA5B1: P = 0.001 ) and pTNM-stage (PDIA3: P = 0.001 ; ITGA5B1: P = 0.009 ). Furthermore, we found that, compared with the current TNM staging system, the molecular model elicited from the expression of MYC, PDIA3, and ITGA5B1 shows higher accuracy in predicting OS (P < 0.001 ) or DFS (P < 0.001 ) in ESCC patients. Moreover, ROC and regression analysis demonstrated that this model was an independent predictor for OS and DFS, which could also help determine a subgroup of ESCC patients that may benefit from chemoradiotherapy. In conclusion, our study has identified a novel molecular prognosis model, which may serve as a complement for current clinical risk stratification approaches and provide potential therapeutic targets for ESCC treatment.